Viridian Therapeutics, Inc.

This study tested a new drug called VRDN-003 in 87 people with thyroid eye disease (TED). The drug is given as a shot under the skin and targets a protein linked to the disease. The main goal was to check safety and how the drug moves through the body, not yet to measure how well…

This study tested an investigational drug called VRDN-001 in 143 people with thyroid eye disease who did not improve in earlier studies. The drug aims to reduce inflammation and eye bulging by blocking a specific receptor. Researchers measured how many participants had at least a…

This completed Phase 3 trial tested a drug called VRDN-001 in 231 people with thyroid eye disease (TED). The drug works by blocking a receptor involved in inflammation and swelling. The main goal was to check safety and tolerability, with secondary goals including measuring chang…

This Phase 3 trial tested an investigational drug called veligrotug (VRDN-001) in 188 people with chronic thyroid eye disease. The drug is an antibody that blocks a protein involved in the disease. The main goal was to see if it could reduce eye bulging (proptosis) compared to a …